UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

 

Amendment No. 2

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended June 30, 2017

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period from ____________ to ____________

 

Commission File Number: 000-33167

 

KIWA BIO-TECH PRODUCTS GROUP CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   77-0632186

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

3200 Guasti Road, Suite #100,

Ontario, California

  91761
(Address of principal executive offices)   (Zip Code)

 

(909) 456-8828

(Registrant’s telephone number, including area code)

 

 

310 N. Indian Hill Blvd., #702

Claremont, California 91711

 
  (Former address)  

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
   
Non-accelerated filer [  ] Smaller reporting company [X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

There were 16,885,260 shares of the issuer’s common stock outstanding as of March 14, 2019.

 

 

 

     
     

 

Explanatory Note

 

The purpose of this Amendment No. 2 to Kiwa Bio-Tech Products Group Corporation’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2017 (the “Form 10-Q”), as filed with the Securities and Exchange Commission on March 15, 2019, is to furnish Exhibits 101 to the Form 10-Q in accordance with Rule 201(c) and Rule 405 of Regulation S-T. Exhibits 101 provide the financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). This Amendment No. 2 to the Form 10-Q also updates the Exhibit Index to reflect the furnishing of Exhibits 101.

 

No other changes have been made to the Form 10-Q. This Amendment No. 2 to the Form 10-Q continues to speak as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way the disclosures made in the original Form 10-Q.

 

     
     

 

Item 6. Exhibits.

 

Exhibit

No.

  Description  

Filed

Herewith

         
31.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   *
         
31.2   Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002   *
         
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   *
         
101.INS †   XBRL Instance Document   X
101 SCH †   XBRL Taxonomy Extension Schema Document   X
101.CAL †   XBRL Taxonomy Extension Calculation Linkbase Document   X
101 LAB †   XBRL Extension Labels Linkbase Document   X
101.PRE †   XBRL Taxonomy Extension Presentation Linkbase Document   X
101.DEF †   XBRL Taxonomy Extension Definition Linkbase Document   X

 

*

Filed as an exhibit to the amended Form 10-Q for the quarter ended June 30, 2017, filed March 15, 2019.

   
X Filed herewith
 
In accordance with SEC rules, this interactive data file is deemed “furnished” and not “filed” for purposes of Sections 11 or 12 of the Securities Act of 1933 and Section 18 of the Securities and Exchange Act of 1934, and otherwise is not subject to liability under those sections or acts.

 

     
     

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  KIWA BIO-TECH PRODUCTS GROUP CORPORATION
     
March 15, 2019 By: /s/ Yvonne Wang
    Yvonne Wang, Interim Chief Executive Officer and Interim Chief Financial Officer

 

     
     

Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kiwa Bio Tech Products (CE) Charts.
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kiwa Bio Tech Products (CE) Charts.